| Literature DB >> 27564141 |
Zvia Agur1, Karin Halevi-Tobias1, Yuri Kogan1, Ofer Shlagman1.
Abstract
INTRODUCTION: Recently, cancer immunotherapy has shown considerable success, but due to the complexity of the immune-cancer interactions, clinical outcomes vary largely between patients. A possible approach to overcome this difficulty may be to develop new methodologies for personal predictions of therapy outcomes, by the integration of patient data with dynamical mathematical models of the drug-affected pathophysiological processes. AREAS COVERED: This review unfolds the story of mathematical modeling in cancer immunotherapy, and examines the feasibility of using these models for immunotherapy personalization. The reviewed studies suggest that response to immunotherapy can be improved by patient-specific regimens, which can be worked out by personalized mathematical models. The studies further indicate that personalized models can be constructed and validated relatively early in treatment. EXPERT OPINION: The suggested methodology has the potential to raise the overall efficacy of the developed immunotherapy. If implemented already during drug development it may increase the prospects of the technology being approved for clinical use. However, schedule personalization, per se, does not comply with the current, 'one size fits all,' paradigm of clinical trials. It is worthwhile considering adjustment of the current paradigm to involve personally tailored immunotherapy regimens.Entities:
Keywords: Mathematical model; adoptive cell transfer; cancer vaccination; immune checkpoint inhibitor; immunotherapy personalization; model validation
Year: 2016 PMID: 27564141 DOI: 10.1080/14712598.2016.1223622
Source DB: PubMed Journal: Expert Opin Biol Ther ISSN: 1471-2598 Impact factor: 4.388